$TRVN “We continue to make steady progress on all fronts to gather the information needed to resubmit the NDA for oliceridine,” said Carrie Bourdow, President and Chief Executive Officer. “I am pleased that we have finished the work to address three of the four items outlined in the CRL. Once we receive topline data for the healthy volunteer QT study, which we are on schedule to report next quarter, we look forward to resubmitting the NDA as early as possible in the first quarter of next year.”
  • 5
  • 2